HHS Public Access

Author manuscript

Stroke. Author manuscript; available in PMC 2023 April 01.

Published in final edited form as:

Stroke. 2022 April ; 53(4): 1199–1206. doi:10.1161/STROKEAHA.121.034130.

Cerebrovascular Risk-Factors of Prevalent and Incident Brain Infarcts in the General Population:The AGES-Reykjavik Study

Sigurdur Sigurdsson, MSc[1,*], **Thor Aspelund, PhD**[1,2], **Olafur Kjartansson, MD**[1], **Elias Gudmundsson, MSc**[1], **Palmi V. Jonsson, MD, PhD**[2], **Mark A. van Buchem, MD, PhD**[3], **Vilmundur Gudnason, MD, PhD**[1,a,2], **Lenore J. Launer, PhD**[4,a]

[1]The Icelandic Heart Association, Kopavogur, Iceland

[2]The University of Iceland, Reykjavik, Iceland

[3]Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands

[4]Laboratory of Epidemiology, Demography, and Biometry, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA

Abstract

Background and Purpose—Studies on the association of cerebrovascular risk-factors to MRI (magnetic resonance imaging) detected brain infarcts have been inconsistent, partly reflecting limits of assessment to infarcts anywhere in the brain, as opposed to specific brain regions. We hypothesized that risk-factors may differ depending on where the infarct is located in subcortical-, cortical- and cerebellar regions.

Methods—Participants (n=2662, mean age 74.6±4.8) from the longitudinal population-based Age, Gene/Environment Susceptibility (AGES)-Reykjavik Study underwent brain MRI at baseline and on average 5.2 years later. We assessed the number and location of brain infarcts (prevalent vs incident). We estimated the risk-ratios of prevalent (PRR) and incident (IRR) infarcts by baseline cerebrovascular risk-factors using Poisson regression.

Results—Thirty-one percent of the study participants had prevalent brain infarcts and 21% developed new infarcts over 5 years. Prevalent subcortical infarcts were associated with hypertension (PRR 2.7 (95%CI, 1.1–6.8)), systolic blood-pressure (PRR 1.2 (95%CI, 1.1–1.4)) and diabetes (PRR 2.8 (95%CI, 1.9–4.1)); incident subcortical infarcts were associated with systolic (IRR 1.2 (95%CI, 1.0–1.4)) and diastolic (IRR 1.3 (95%CI, 1.0–1.6)) blood pressure. Prevalent and incident cortical infarcts were associated with carotid plaques (PRR 1.8 (95%CI,

[*]*Corresponding author*: Sigurdur Sigurdsson. The Icelandic Heart Association, 201 Kopavogur, ICELAND, Tel: + 354 5351867, sigurdur@hjarta.is, Twitter: @SigurdurSigurd8.

[a]These authors share senior authorship

Author social media handle; Facebook:https://www.facebook.com/profile.php?id=100000201519740

Disclosures

None.

Supplemental Materials

Expanded Materials & Methods

Tables I–IX

Figure I

Reference 11

1.3–2.5 and (IRR 1.9 (95%CI, 1.3–2.9)) respectively)) and atrial fibrillation was significantly associated with prevalent cortical infarcts (PRR 1.8 (95%CI, 1.2–2.7)). Risk-factors for prevalent cerebellar infarcts included hypertension (PRR 2.45 (95%CI, 1.5–4.0)), carotid plaques, (PRR 1.45 (95%CI, 1.2–1.8)) and migraine with aura (PRR 1.6 (95%CI, 1.1–2.2)). Incident cerebellar infarcts were only associated with any migraine (IRR 1.4 (95%CI, 1.0–2.0)).

Conclusions—The risk for subcortical infarcts tends to increase with small vessel disease risk-factors such as hypertension and diabetes. Risk for cortical infarcts tends to increase with atherosclerotic/coronary processes, and risk for cerebellar infarcts with a more mixed profile of factors. Assessment of risk-factors by location of asymptomatic infarcts found on MRI may improve the ability to target and optimize preventive therapeutic approaches to prevent stroke.

Keywords

MRI; Brain infarcts; Cerebrovascular risk-factors; Cohort studies

Introduction

Brain infarcts in older persons are common findings on magnetic resonance (MR) images and most do not cause signs or symptoms that are clinically diagnosed as stroke.[1, 2] It is unclear why most infarcts tend to be asymptomatic. It has been suggested that this may be associated with size and location of infarcts.[3] Asymptomatic infarcts have been associated with higher risk of stroke, dementia and early mortality.[4] Results on the prevalence and incidence of brain infarcts have differed across population based studies and the association of brain infarcts with risk-factors have reported inconsistent and conflicting findings. As demonstrated in a systematic review[5], results on the association of brain infarcts with risk-factors in cohort studies have varied greatly with only age and hypertension consistently shown as significant risk-factors. Significant associations between infarcts and heart failure, carotid and coronary artery disease are likely. However, the association between infarcts and potential risk-factors including sex, tobacco consumption, dyslipidemia, atrial fibrillation and diabetes mellitus remains unclear.[5] While clinical strokes are characterized by risk-factors and location most MRI-defined “asymptomatic” infarcts are limited to infarcts anywhere in the brain without separate assessment for infarct subtypes.

In this study we assessed the association of MRI identified prevalent and incident brain infarcts located in the subcortical, cortical and cerebellar regions to vascular, atherosclerotic and embolic risk-factors. Data are from a large well-described population-based cohort of older men and women participating in the Age Gene/Environment Susceptibility-Reykjavik Study (AGES-Reykjavik Study).

Materials and Methods

Data availability

Data from the AGES-Reykjavik study are available through collaboration (AGES_data_request@hjarta.is) under a data usage agreement with the IHA.

Study population

The AGES-Reykjavik Study described previously[6] is a population-based study aimed to investigate the genetic and environmental factors contributing to clinical and subclinical disease at older age. The baseline exam (2002–2006) on 5764 men and women, was followed by a second exam 5 years later from 2007 to 2011. The AGES-Reykjavik Study has been approved by the Icelandic National Bioethics Committee and by the Institutional Review Board for the Intramural Research Program of the National Institute on Aging, National Institutes of Health, USA. Written informed consent was obtained from all participants.

MRI acquisition and rating of infarcts

Identical MRI acquisition protocols were used at both time-points. Standardized criteria were established to reliably identify brain infarcts in the cortical, subcortical and cerebellar regions and excluding subcortical lesions smaller than 4 mm to minimize misdiagnosis of dilated perivascular spaces.[7] The identification of subcortical infarcts was made in accordance with expert guidance that provided definitions and neuroimaging standards for markers and consequences of small vessel disease (SVD).[8] The MRI acquisition and semi-quantitative rating of brain infarcts have been described elsewhere,[9] and are also described in detail together with the rating reliability in the Data Supplement.

Cerebrovascular risk-factors

These include hypertension, systolic- and diastolic blood pressure, diabetes, smoking, atrial fibrillation (AF), the presence of carotid plaques, migraine, total cholesterol, high-density lipoprotein cholesterol (HDL) and Agatston coronary artery calcium, a marker of atherosclerosis. Blood pressure was assessed from the mean value of two measurements using a large-cuff mercury sphygmomanometer. Hypertension (current or former) was defined as measured systolic blood pressure 140 mmHg or higher, diastolic blood pressure 90 mmHg or higher, self-reported doctors diagnosis of hypertension, or use of antihypertensive medications. Diabetes mellitus (DM) was defined as history of diabetes, use of glucose-modifying medication, or fasting blood glucose of more than 7 mmol/L. Smoking status was assessed by questionnaire in categories of current and noncurrent (never/former) smokers. Atrial fibrillation was identified by reviewing hospital records and private physicians records for all participants with the hospital discharge diagnosis codes for AF from any hospital in Reykjavik from January 1, 1987 until the day of the study examination, and by reviewing a 12-lead ECG performed during the baseline study visit. The AF classification for this study included those with persistent or paroxysmal AF.[10] The assessment of carotid plaque was based on imaging with ultrasound of a predefined segment in each common carotid artery. Of the left and right carotid bifurcation and internal carotid artery the presence of a plaque was assessed semi-quantitatively. The most severe lesion per location were assessed as none, minimal, moderate and severe. In this study, only plaques at least moderate in size were included. The definition of a moderate plaque was at least one, clear, reasonable easy to be visualized plaque causing at least some diameter reduction of the vessel lumen. Migraine was defined as self-reported doctors diagnosis of migraine headache, current or former. Positives were subclassified into those who had experienced visual aura

with headaches or not. High-density lipoprotein cholesterol were measured in fasting blood samples using reagents from Roche Diagnostics (Mannheim, Germany) on a Hitachi 912 analyzer (Hitachi Ltd., Tokyo, Japan), according to the manufacturers instructions. Coronary calcium Agatston score, was measured using computed tomography.

Symptomatic infarcts

Prevalent strokes were obtained from medical records (69 of 2662 participants (3%)), 14% (11 of 69 participants) of which were adjudicated by a dementia neurologist, a stroke neurologist and a neuroradialogist. This same adjudication process was used to diagnose all incident strokes, which included strokes that occurred between the 1st and 2nd MRI (average 5.2 years between). Based on mortality records, 49 of 520 (9%) deaths among participants with baseline data occurred because of stroke before invitation to the follow-up study.

Analytic sample

Of the 5764 participants in the baseline study, 4766 had baseline MRI. Participants with MRI at baseline and not included in the final sample with follow-up MRI were older, had more coronary calcium, were more likely to be smokers, to have hypertension, diabetes, carotid plaque and atrial fibrillation.

Of the 4766 baseline participants, there were 3316 participants who attended the follow-up study and 2662 participants (1097 men and 1565 women) who had a second MRI and were included in the final sample. The reasons for no follow-up MRI were: MRI contraindications (n=391) and claustrophobia (n=204), disability or refusals (n=59). Compared to these participants, the 654 excluded persons were more often men, more likely to be older, to have hypertension, diabetes and atrial fibrillation (please see Figure I, Study Flow Diagram in Data Supplement). Of the 2662 subjects in the final sample less than 1% had missing values for each risk-factor except for carotid plaques where 5% had missing values. Available case analysis was performed. Sensitivity analysis using multiple imputation for missing data for the risk-factors did not change the results (data not shown).

Statistical analysis

All analyses were performed with PROC-GENMOD and PROC-LOGISTIC in SAS/STAT®9.2 (SAS Institute Inc). The relative risks (risk-ratios, RRs) were estimated using a Poisson regression model with a robust sandwich variance estimator and presented with 95% confidence intervals (95%CI). The risk-ratios of prevalent infarcts (PRR) in relation to risk-factors one at a time (univariate analysis) were estimated after adjusting for age and sex. The risk-ratios of incident infarcts (IRR) in relation to risk-factors were additionally adjusted for the time interval between MR scans. The risk-ratios of infarcts in relation to total cholesterol and HDL were additionally adjusted for the use of lipid lowering medication.

To determine the association of risk-factors with infarcts independent of one another, a multivariate analysis was conducted using Poisson regression, including risk-factors that showed significant associations with infarcts in the univariate analysis. To test the robustness of the Poisson models a sensitivity analysis was performed using logistic regression.

To test the hypothesis that risk-factor effects vary depending on the location of brain infarcts we assessed the interaction across brain regions for each risk-factor. We also assessed the interaction between the various risk-factors in a multivariable model to test for effect modification (for detail, please see Data Supplement).

The present study utilized STROBE reporting guidelines[12] (Data Supplement).

Results

Compared to those with no infarcts, participants with brain infarcts were more likely to be older, to have hypertension, migraine with visual aura, diabetes, atrial fibrillation, to use lipid lowering medication (statins in 99% of cases), to use blood pressure medication, to use anticoagulation medication and to have more coronary calcium (age adjusted p-value for all <0.05) (Table 1). The average time between baseline and follow-up assessments was 5.2±0.2 (mean±SD) years. In this sample of 2662 persons, 826 (31%) had prevalent infarcts and 559 (21%) new infarcts. Of those individuals with prevalent infarcts, 441 (53%) had only one infarct and 385 (47%) had two or more infarcts. Of those with new infarcts, 335 (60%) had only one new infarct and 224 (40%) had two or more new infarcts. For more detailed number of infarcts rated per individual, overall and by subregions, please see Tables I and II in Data Supplement. Of those with prevalent infarcts on MRI, only 5% had clinically recorded events and of those with new infarcts on MRI, 7% had clinically recorded events. Among those cases, 3% of individuals with prevalent infarcts and 2% of individuals with incident infarcts had evidence of prior transient ischemic attack. For subcortical-, cortical- and cerebellar infarcts the prevalence was 7.6%, 11.2% and 20.9% respectively and the cumulative incidence over 5 years, 4.5%, 7.9% and 13.0% respectively (Table 2). The risk of infarcts in all regions increased significantly with increasing age, except for incident subcortical infarcts where the increased risk was marginally significant. The age adjusted risk of both prevalent and incident infarcts was higher in men compared to women in all infarct regions, with cortical infarcts having the strongest sex difference and cerebellar the smallest (Table 3 & Table 4).

Association between cerebrovascular risk-factors and prevalent infarcts

Of the cerebrovascular risk-factors included in this study, hypertension, elevated systolic blood-pressure, diabetes and coronary calcium all significantly associated the presence of infarcts overall and specifically subcortical infarcts. Of those same risk-factors, only coronary calcium was significantly associated with cortical infarcts whereas hypertension and coronary calcium were significantly associated with cerebellar infarcts (Table 3).

Atrial fibrillation, carotid plaques, the use of lipid lowering medication and coronary calcium were significantly associated with infarcts overall and specifically with cortical infarcts. These same risk-factors except for atrial fibrillation were significantly associated with cerebellar infarcts while none except for coronary calcium associated subcortical infarcts (Table 3).

Migraine with visual aura was significantly associated with prevalent infarcts overall and specifically cerebellar infarcts. The association of diastolic blood-pressure, smoking,

migraine overall, total cholesterol and HDL with infarcts was non-significant for all infarct regions (Table 3).

Association between cerebrovascular risk-factors and incident infarcts

Elevated systolic- and diastolic blood pressure were significantly associated with new subcortical infarcts; carotid plaques and coronary calcium were associated with infarcts overall and specifically new cortical infarcts. Hypertension, overall migraine and coronary calcium were significantly associated with incident cerebellar infarcts. Diabetes, smoking, atrial fibrillation, migraine with visual aura, the use of lipid lowering medication and cholesterol were not significantly associated with incident infarcts (Table 4). Adjusting additionally for the use of antithrombotic medication only slightly altered risk-ratios for some risk-factors without changing the significance.

Risk factor associations stratified by presence or absence of baseline infarcts

Of the 1836 persons without infarcts at baseline, 258 (14.1%) had at least one new infarct detected on the second MRI, while of the 826 persons with at least one infarct at baseline, 301(36.4%) had at least one new infarct. Having a brain infarct at baseline was strongly associated with developing new infarcts in all brain regions. The age- and sex adjusted relative-risk was strongest for subcortical infarcts, 5.76 (95%CI, 3.89 to 8.52) and least strong for cerebellar infarcts, 2.96 (95%CI, 2.28 to 3.86) (Table 4). Among those with no infarct at baseline, the risk-factors of incident infarcts included age, sex, hypertension and coronary calcium. Sex and hypertension were the strongest risk-factors for new infarcts in the group with prevalent infarcts and coronary calcium were stronger in the group without prevalent infarcts (Table III in Data Supplement). The risk-factor related risk of incident infarcts in the specific subregions did not differ depending on presence or absence of prevalent infarcts (data not shown).

Association between cerebrovascular risk-factors and infarcts based on multivariate analysis

The multivariate analysis showed an attenuation in risk-ratios for most risk-factors due to confounding effects. Yet, most risk-factors that were significantly associated with brain infarcts in the univariate analysis remained significantly associated with infarcts in the multivariate analysis. The use of lipid lowering medication becomes significantly protective for incident brain infarcts in the multivariate analysis. This can be explained by the strong confounding effect of having a prevalent infarct; considerably higher proportion of individuals with prevalent infarcts use lipid lowering medication (30%) compared to individuals without infarcts (20%) (Table 1). For results from multivariate analysis please see Tables IV and V in Data Supplement.

Sensitivity analysis using logistic regression models showed similar results with respect to significant associations (Tables VI–IX in Data Supplement).

Tests for difference in effects size across brain regions for each of the risk-factors showed that for prevalent infarcts there was a statistically significant difference in the effect size associated with diabetes (p=0.007) among the brain regions as shown in Table 3. For

incident infarcts there was a statistically significant difference in the effect size associated with prevalent infarct (p=0.04) and carotid plaque (p=0.01) among the brain regions as shown in Table 4.

None of the tests for interactions of the risk-factors were statistically significant at the significance level for interactions. Interactions with sex were not significant.

Discussion

In this study, prevalent and incident infarcts in different brain regions detected with MRI were associated with different risk-factor profiles. Cerebrovascular risk-factors that have been shown consistently in other studies to be associated with SVD including elevated systolic- and diastolic blood pressure, hypertension and diabetes were associated with higher risk of subcortical infarcts than with cortical infarcts. The embolic risk-factors, carotid plaques and atrial fibrillation were more likely to be associated with cortical infarcts than with subcortical- and cerebellar infarcts. Furthermore, migraine was specifically associated with cerebellar infarcts. Otherwise, cerebellar infarcts share risk-factors with subcortical- and cortical infarcts. Although brain infarcts at baseline were strongly associated with new infarcts in all brain regions, the risk of new infarcts by cerebrovascular risk-factors was similar between those with vs without prevalent infarcts.

A major strength of this study was the available information of prevalent and incident infarcts by brain region, making it possible to explore if different risk-factors exist for the various infarct subtypes. There are three different major causes of brain infarcts. On average, approximately 50% of infarcts are due to large vessel atherosclerosis and rupture of an atherosclerotic plaque, 20% are caused by cardio embolism and approximately 25% are thought to manifest as lacunar infarcts due to small vessel disease and probably occlusion of deep perforating arteries.[13] Small vessel pathologies are thought to be the most common cause of subcortical infarcts (lacunes), although the underlying mechanism is unclear.[14] Pathophysiologic processes thought to contribute to subcortical infarcts include endothelial and vascular dysfunction, arteriosclerosis, lipohyalinosis, arteriolosclerosis, glycation of proteins and deposition of B-amyloid in the vessel wall,[15, 16] leading to occlusion of the vessel.[14] Another characteristic of SVD is the deposition of amyloid-beta (Aβ) protein in cerebral blood vessel walls (cerebral amyloid angiopathy (CAA)),[17, 18] which may lead to impaired autoregulation, endothelial dysfunction, thickening of the vessel wall or even vessel occlusion, thereby inducing hypoperfusion and ischemia around the amyloid affected vessels.[19] There has been a widespread view that subcortical infarcts are mainly caused by damage to small arterioles by high blood pressure, with lipohyalinosis or fibrinoid necrosis. When these small vessels occlude the result is lacunar infarction.[20] Diabetes mellitus is another risk-factor traditionally linked with infarcts from small vessels. In diabetes, it is assumed that glycation of proteins and diffuse basement membrane thickening leads to narrowing of the vessel lumen and tortuosity, which lengthens the distance blood must travel to perfuse its targets, resulting in lacunar infarcts.[21]

Emboli becomes the most frequent cause of brain infarcts with increasing age.[22] Most emboli are fragments of blood clots that originate in the heart or major vessels.

Conditions causing cardiac emboli include myocardial infarcts, atrial fibrillation, rheumatic heart disease, mitral valve prolapse, prosthetic heart valve, calcified mitral annulus and cardiomyopathy.[23] Some emboli consist of atheromatous material that is detached from ulcerated atheromas of the aorta or carotid arteries.[24, 25] Cholesterol crystals from ruptured plaques may embolize distal vessels.[26]

In this study, atrial fibrillation was only significantly associated with prevalent cortical infarcts. The presence of carotid plaque was significantly associated with cortical and cerebellar infarcts but not with subcortical infarcts A possible explanation for the association between carotid plaques and cerebellar infarcts may be emboli arising from the vertebrobasilar arteries or the aortic arch due to increased atherosclerotic burden in individuals with carotid plaques compared to those without carotid plaques. There was a significant association between coronary artery calcium and all prevalent infarct subtypes. This relationship was stronger for cortical and cerebellar infarcts than for subcortical infarcts. However, only incident cortical- and cerebellar infarcts were significantly associated with coronary artery calcium. These findings emphasize the relationship between cortical and cerebellar infarcts and underlying conditions resulting in emboli contrary to the subcortical infarcts.

A major finding in this study was the association of self-reported doctors diagnosis of migraine headache with both prevalent and incident infarcts. Migraine was first linked to MRI detected brain infarcts in the population-based CAMERA study.[27] That study showed an increased risk of cerebellar infarcts in individuals with migraine, especially migraine with aura, compared to controls. Since then, several cross-sectional population-based studies have shown similar findings,[28–30] and we reported an association of aura in mid-life to late-life prevalent cerebellar infarcts on MRI in the AGES-Reykjavik cohort.[31] Longitudinal MRI studies on the relationship between migraine and brain infarcts are scarce. A 9-year follow-up of the CAMERA study did not show significantly higher incidence of brain infarcts in migraineurs compared to non-migraineurs based on MRIs from two time-points.[32] The pathogenic mechanisms clarifying the migraine- brain infarct association remain poorly understood, but a few theories exist including cortical spreading depression, vasoconstriction, endovascular dysfunction, shared genetic defects and neurogenic inflammation.[33] The cerebellar predilection of infarcts in migraine has been suggested to be caused by hemodynamical changes such as altered autoregulation in the posterior circulation territory.[34] Nervous tissues of the posterior fossa may be more vulnerable to ischemic damage than other regions of the brain due to comparatively reduced capacity to adapt to a sudden hemodynamic change.[35] To the best of our knowledge this study is the first study to show association between migraine and incident infarcts based on MRIs at two time-points.

It is well known that smoking is a leading cause of morbidity and mortality in virtual every country in the world[36] where risk-ratios of all-cause mortality in current versus never-smokers has been consistently reported at 2.8 to 3.0.[37–39] The lack of significant association of smoking with brain infarcts in this study and most other studies is likely because smokers among study participants have died prior to the study entry so that surviving smokers in our sample may have been those least likely to develop smoking-related brain infarcts.

Most studies examining brain infarcts do not support a sex disparity in infarct risk.[5] However, the risk of prevalent and incident infarcts overall in men compared to women in this study was almost 2-fold higher and almost 3-fold higher in the cortical region. A likely explanation for this is the generally worse risk-factor profile in men as demonstrated in another study of this cohort.[40]

The multivariate analysis in this study demonstrated the protective effect of lipid lowering medication (statins in 99% of cases) on new infarcts. This finding agrees with the results from another longitudinal cohort study that observed that those treated with statins had a lower incidence of asymptomatic brain infarcts compared with those who were untreated.[41] It is of interests that the use of lipid lowering medication in this study was independently associated with lower risk of new infarcts. Cumulative evidence has suggested that statins, in addition to lowering low-density lipoprotein (LDL) cholesterol, may exhibit pleiotropic effects including plaque stabilization and endothelial homeostasis that counteract the incidence of stroke and reduce vascular event rate in general.[42]

Other strengths of the present study include the very large well-characterized longitudinal sample of older individuals, the use of a standardized MRI acquisition and brain infarct rating protocols. However, of the individuals that attended the follow-up visit with available MRI and included in the analysis compared to those without MRI and excluded were younger and healthier. Similarly, individuals that only attended the baseline study and not the follow-up were significantly older and had more cerebrovascular risk-factors than those included in the follow-up study. This may have resulted in an underestimation of infarcts and in bias if the relationships among risk-factors, presence and location of infarcts differed between the included and excluded persons. Another limitation is that the risk-factor level may have changed between the baseline MRI and incident infarcts, therefore subjects may have been incorrectly classified based on risk-factors that emerged during the follow-up period.

Conclusions

Infarcts in different brain regions detected with MRI have different risk-factor profiles. Majority of these infarcts are asymptomatic. Therefore, it is important to not limit the assessment of risk-factors to infarcts anywhere in the brain and include subregions. Individuals with history of migraine are more likely to sustain new infarcts and men are at higher risk than women of having infarcts. The use of lipid lowering medication is independently associated with lower risk of new infarcts. This information may aid with targeting and optimizing preventive therapeutic approaches for clinical stroke emphasizing the importance of controlling for the risk-factors in the population at large, not only those with manifest cerebral disease.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The study is approved by the Icelandic National Bioethics Committee, VSN:00-063 and the IRB responsible for the National Institute on Aging (NIA) research. The researchers are indebted to the participants for their willingness to participate in the study.

Sources of Funding

This study has been funded by NIH-contract N01-AG-1-2100, the NIA Intramural-Research-Program, Hjartavernd and the Icelandic Parliament.

Non-standard Abbreviations and Acronyms

SVD	small vessel disease
HDL	high-density lipoprotein cholesterol
LDL	low-density lipoprotein cholesterol
AF	atrial fibrillation
IRR	risk-ratios of incident infarcts
PRR	risk-ratios of prevalent infarcts

References

1. Longstreth WT, Dulberg C, Manolio TA, Lewis MR, Beauchamp NJ, O'Leary D, Carr J, Furberg CD. Incidence, manifestations, and predictors of brain infarcts defined by serial cranial magnetic resonance imaging in the elderly: The cardiovascular health study. Stroke. 2002;33:2376–2382 [PubMed: 12364724]
2. Vermeer SE, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MMB. Prevalence and risk factors of silent brain infarcts in the population-based rotterdam scan study. Stroke. 2002;33:21–25 [PubMed: 11779883]
3. Fanning JP, Wesley AJ, Wong AA, Fraser JF. Emerging spectra of silent brain infarction. Stroke. 2014;45:3461–3471 [PubMed: 25293663]
4. Bokura H, Kobayashi S, Yamaguchi S, Iijima K, Nagai A, Toyoda G, Oguro H, Takahashi K. Silent brain infarction and subcortical white matter lesions increase the risk of stroke and mortality: A prospective cohort study. J Stroke Cerebrovasc Dis. 2006;15:57–63 [PubMed: 17904049]
5. Fanning JP, Wong AA, Fraser JF. The epidemiology of silent brain infarction: A systematic review of population-based cohorts. BMC Medicine. 2014;12:119–119 [PubMed: 25012298]
6. Harris TB, Launer LJ, Eiriksdottir G, Kjartansson O, Jonsson PV, Sigurdsson G, Thorgeirsson G, Aspelund T, Garcia ME, Cotch MF, et al. Age, gene/environment susceptibility–reykjavik study: Multidisciplinary applied phenomics. American Journal of Epidemiology. 2007;165:1076–1087 [PubMed: 17351290]
7. Zhu Y-C, Dufouil C, Tzourio C, Chabriat H. Silent brain infarcts. A Review of MRI Diagnostic Criteria. 2011;42:1140–1145
8. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, Lindley RI, O'Brien JT, Barkhof F, Benavente OR, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurology. 2013;12:822–838 [PubMed: 23867200]
9. Sigurdsson S, Aspelund T, Kjartansson O, Gudmundsson EF, Jonsdottir MK, Eiriksdottir G, Jonsson PV, van Buchem MA, Gudnason V, Launer LJ. Incidence of brain infarcts, cognitive change, and risk of dementia in the general population. The AGES-Reykjavik Study (Age Gene/Environment Susceptibility-Reykjavik Study). 2017;48:2353–2360

10. Stefansdottir H, Arnar DO, Aspelund T, Sigurdsson S, Jonsdottir MK, Hjaltason H, Launer LJ, Gudnason V. Atrial fibrillation is associated with reduced brain volume and cognitive function independent of cerebral infarcts. Stroke. 2013;44:1020–1025 [PubMed: 23444303]
11. Zellner A (1962). An efficient method of estimating seemingly unrelated regression equations and test for aggregation bias. Journal of American Statistical Association, 57, 348–368
12. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, VandenbrouckeJP; STROBE Initiative. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147:573–577 [PubMed: 17938396]
13. Sommer CJ. Ischemic stroke: Experimental models and reality. Acta Neuropathologica. 2017;133:245–261 [PubMed: 28064357]
14. Shi Y, Wardlaw JM. Update on cerebral small vessel disease: A dynamic whole-brain disease. Stroke and Vascular Neurology. 2016;1:83–92 [PubMed: 28959468]
15. Jellinger KA. Pathology and pathogenesis of vascular cognitive impairment—a critical update. Frontiers in Aging Neuroscience. 2013;5:17 [PubMed: 23596414]
16. Wesołowski W, Dziewulska D, Koziarska M, Iżycka-Świeszewska E. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (cadasil) – literature review apropos an autopsy case. Polish Journal of Pathology. 2015;66:323–329 [PubMed: 26619111]
17. Vinters HV. Cerebral amyloid angiopathy. A critical review. Stroke. 1987;18:311 [PubMed: 3551211]
18. Banerjee G, Carare R, Cordonnier C, Greenberg SM, Schneider JA, Smith EE, Buchem Mv, Grond Jvd, Verbeek MM, Werring DJ. The increasing impact of cerebral amyloid angiopathy: Essential new insights for clinical practice. Journal of Neurology, Neurosurgery & Psychiatry. 2017;88:982
19. Reijmer YD, van Veluw SJ, Greenberg SM. Ischemic brain injury in cerebral amyloid angiopathy. Journal of Cerebral Blood Flow & Metabolism. 2016;36:40–54 [PubMed: 25944592]
20. Blanco PJ, Müller LO, Spence JD. Blood pressure gradients in cerebral arteries: A clue to pathogenesis of cerebral small vessel disease. Stroke and Vascular Neurology. 2017;2:108–117 [PubMed: 28989801]
21. Østergaard L, Engedal TS, Moreton F, Hansen MB, Wardlaw JM, Dalkara T, Markus HS, Muir KW. Cerebral small vessel disease: Capillary pathways to stroke and cognitive decline. Journal of Cerebral Blood Flow & Metabolism. 2016;36:302–325 [PubMed: 26661176]
22. Starby H, Delavaran H, Andsberg G, Lövkvist H, Norrving B, Lindgren A. Multiplicity of risk factors in ischemic stroke patients: Relations to age, sex, and subtype - a study of 2,505 patients from the lund stroke register. Neuroepidemiology. 2014;42:161–168 [PubMed: 24556909]
23. Amarenco P, Bogousslavsky J, Caplan LR, Donnan GA, Hennerici MG. New approach to stroke subtyping: The a-s-c-o (phenotypic) classification of stroke. Cerebrovascular Diseases. 2009;27:502–508 [PubMed: 19342826]
24. Amarenco P, Cohen A, Tzourio C, Bertrand B, Hommel M, Besson G, Chauvel C, Touboul P-J, Bousser M-G. Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. New England Journal of Medicine. 1994;331:1474–1479
25. Lyaker MR, Tulman DB, Dimitrova GT, Pin RH, Papadimos TJ. Arterial embolism. International Journal of Critical Illness and Injury Science. 2013;3:77–87 [PubMed: 23724391]
26. Saric M, Kronzon I. Aortic atherosclerosis and embolic events. Current Cardiology Reports. 2012;14:342–349 [PubMed: 22437371]
27. Kruit MC, van Buchem MA, Hofman PM, et al. Migraine as a risk factor for subclinical brain lesions. JAMA. 2004;291:427–434 [PubMed: 14747499]
28. Monteith TS, Gardener H, Rundek T, Elkind MSV, Sacco RL. Migraine and risk of stroke in older adults: Northern manhattan study. Neurology. 2015;85:715–721 [PubMed: 26203088]
29. Kurth T, Mohamed S, Maillard P, Zhu Y-C, Chabriat H, Mazoyer B, Bousser M-G, Dufouil C, Tzourio C. Headache, migraine, and structural brain lesions and function: Population based epidemiology of vascular ageing-mri study. The BMJ. 2011;342:c7357 [PubMed: 21245119]
30. Bashir A, Lipton RB, Ashina S, Ashina M. Migraine and structural changes in the brain. A systematic review and meta-analysis. 2013;81:1260–1268

31. Scher AI, Gudmundsson LS, Sigurdsson S, Ghambaryan A, Aspelund T, Eiriksdottir G, van Buchem MA, Gudnason V, Launer LJ. Migraine headache in middle-age and late-life brain infarcts: The age gene/environment susceptibility - reykjavik study. JAMA : the journal of the American Medical Association. 2009;301:2563–2570 [PubMed: 19549973]
32. Palm-Meinders IH, Koppen H, Terwindt GM, Launer LJ, Konishi J, Moonen JME, Bakkers JTN, Hofman PAM, van Lew B, Middelkoop HAM, et al. Structural brain changes in migraine. JAMA. 2012;308:1889–1896 [PubMed: 23150008]
33. Gryglas A, Smigiel R. Migraine and stroke: What's the link? What to do? Current Neurology and Neuroscience Reports. 2017;17:22 [PubMed: 28283957]
34. Reinhard M, Schork J, Allignol A, Weiller C, Kaube H. Cerebellar and cerebral autoregulation in migraine. Stroke. 2012;43:987–993 [PubMed: 22343638]
35. Silvestrini M, Baruffaldi R, Bartolini M, Vernieri F, Lanciotti C, Matteis M, Troisi E, Provinciali L. Basilar and middle cerebral artery reactivity in patients with migraine. Headache: The Journal of Head and Face Pain. 2004;44:29–34
36. Stanaway JD, Afshin A, Gakidou E, Lim SS, Abate D, Abate KH, Abbafati C, Abbasi N, Abbastabar H, Abd-Allah F, et al. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: A systematic analysis for the global burden of disease study 2017. The Lancet. 2018;392:1923–1994
37. Thun MJ, Carter BD, Feskanich D, Freedman ND, Prentice R, Lopez AD, Hartge P, Gapstur SM. 50-year trends in smoking-related mortality in the united states. New England Journal of Medicine. 2013;368:351–364
38. Pirie K, Peto R, Reeves GK, Green J, Beral V. The 21st century hazards of smoking and benefits of stopping: A prospective study of one million women in the uk. The Lancet. 2013;381:133–141
39. Lam TH, Xu L, Jiang CQ, Zhang WS, Zhu F, Jin YL, Thomas GN, Cheng KK. High relative risk of all-cause mortality attributed to smoking in china: Guangzhou biobank cohort study. PLOS ONE. 2018;13:e0196610 [PubMed: 29698485]
40. Veronese N, Sigeirsdottir K, Eiriksdottir G, Marques EA, Chalhoub D, Phillips CL, Launer LJ, Maggi S, Gudnason V, Harris TB. Frailty and risk of cardiovascular diseases in older persons: The age, gene/environment susceptibility-reykjavik study. Rejuvenation Res. 2017;20:517–524 [PubMed: 28602121]
41. Bernick C, Katz R, Smith NL, Rapp S, Bhadelia R, Carlson M, Kuller L. Statins and cognitive function in the elderly The Cardiovascular Health Study. Neurology. 2005;65:1388–1394 [PubMed: 16275825]
42. Fracassi A, Marangoni M, Rosso P, Pallottini V, Fioramonti M, Siteni S, Segatto M. Statins and the Brain: More than Lipid Lowering Agents? Curr Neuropharmacol. 2019;17:59–83 [PubMed: 28676012]

Table 1.

Baseline characteristics of persons without and with prevalent overall infarcts

Characteristics	Without infarcts (n=1836)	With infarcts (n=826)	P-value
Age (years)	74.3±4.7	75.6±4.9	<0.001
Men (%)	37.7	49.0	<0.001
Hypertension (%)	75.6	82.5	<0.001
Systolic BP, mmHg	140.3±19.6	142.9±20.1	0.002
Diastolic BP, mmHg	74.1±9.3	74.3±9.5	0.627
Migraine (%)	12.6	12.9	0.907
Migraine with aura (%)	5.4	7.0	0.118
Diabetes Mellitus (%)	8.0	12.6	<0.001
Use of lipid lowering medication (%)	21.2	29.8	<0.001
Total Cholesterol, mmol/L	5.7±1.1	5.5±1.1	<0.001
High-Density Lipoprotein, mmol/L	1.6±0.4	1.6±0.4	0.096
Smoking (current) (%)	10.8	10.8	1.000
Smoking (quit) (%)	44.1	48.3	0.051
Agatston Coronary Calcium	486.1±799.1	768.0±1061.0	<0.001
Atrial Fibrillation (%)	4.0	8.4	<0.001
Carotid Plaque (≥mod plaque) (%)	59.5	67.6	<0.001
Use of BP lowering medication (%)	57.7	66.2	<0.001
Use of antithrombotic medication (%)	14.3	21.1	<0.001

Abbreviations: SD=Standard deviation, ml=milliliters, BMI=Body Mass Index, BP=Blood pressure, mmHg=millimeter of Mercury, mm=millimeters. Values are unadjusted means ± SD or percentages.

Table 2.

Prevalence and Incidence of Brain Infarcts

Infarct region	Prevalence, n (%)	Incidence, n (%)
Overall	826 (31.0)	559 (21.0)
Subcortical	202 (7.6)	119 (4.5)
Cortical	298 (11.2)	209 (7.9)
Cerebellar	556 (20.9)	346 (13.0)

Values are number and percent of prevalent and incident brain infarcts by brain region in the same sample of 2,662 participants from the AGES-Reykjavik Study.

Table 3.

Relationship between Risk-Factors and Risk of Prevalent Brain Infarcts

	Risk-Ratios of Prevalent Brain Infarcts (RR 95% CI)			
Potential Risk-Factor	**Overall**	**Subcortical**	**Cortical**	**Cerebellar**
Age per 5 years	**1.30 (1.19–1.40)**	**1.43 (1.26–1.63)**	**1.28 (1.10–1.47)**	**1.26 (1.13–1.40)**
Sex (men vs.women)	**1.75 (1.48–2.08)**	**2.03 (1.49–2.77)**	**2.55 (1.92–3.37)**	**1.42 (1.15–1.75)**
Hypertension (yes vs no)	**2.06 (1.41–3.02)**	**2.69 (1.06–6.84)**	1.42 (0.84–2.42)	**2.45 (1.49–4.03)**
Systolic BP	**1.11 (1.02–1.21)**	**1.23 (1.06–1.44)**	1.05 (0.93–1.19)	1.12 (0.99–1.26)
Diastolic BP	1.03 (0.95–1.12)	1.10 (0.96–1.25)	0.94 (0.83–1.06)	1.07 (0.95–1.19)
Diabetes Mellitus (yes vs no)	**1.40 (1.11–1.75)**	**2.81 (1.92–4.11)**	1.31 (0.91–1.89)	1.11 (0.80–1.52)
Smoking (current vs never)	1.26 (0.91–1.74)	1.08 (0.66–1.78)	1.20 (0.76–1.91)	1.33 (0.86–2.06)
Smoking (quit vs never)	1.03 (0.86–1.24)	1.23 (0.86–1.74)	1.01 (0.77–1.33)	1.00 (0.79–1.25)
Atrial Fibrillation	**1.44 (1.08–1.91)**	0.97 (0.50–1.90)	**1.78 (1.17–2.70)**	1.39 (0.99–1.96)
Carotid Plaque (≥mod plaque)	**1.51 (1.26–1.82)**	1.31 (0.92–1.87)	**1.81 (1.32–2.49)**	**1.45 (1.16–1.80)**
Migraine (yes vs no)	1.14 (0.90–1.43)	0.96 (0.58–1.60)	1.11 (0.71–1.74)	1.19 (0.92–1.55)
Migraine with aura (yes vs no)	**1.50 (1.12–2.02)**	1.17 (0.58–2.37)	1.56 (0.84–2.91)	**1.56 (1.13–2.15)**
Use of lipid lowering medication (yes vs no)	**1.63 (1.36–1.95)**	1.39 (0.99–1.96)	**2.02 (1.53–2.68)**	**1.52 (1.21–1.91)**
Total Cholesterol†	0.97 (0.88–1.08)	0.90 (0.75–1.09)	0.96 (0.81–1.14)	1.04 (0.93–1.15)
High-Density Lipoprotein†	0.95 (0.87–1.04)	0.96 (0.80–1.14)	0.98 (0.83–1.14)	0.94 (0.84–1.06)
Agatston Coronary Calcium	**1.31 (1.17–1.46)**	**1.28 (1.06–1.55)**	**1.40 (1.16–1.70)**	**1.27 (1.11–1.46)**

For continuous risk factors, the unit of difference was 1 SD, except for age where it was 5 years. All Risk-Ratios are adjusted for age and sex.

†Additionally adjusted for use of lipid lowering medication.

Table 4.

Relationship between Risk-Factors and Risk of Incident Brain Infarcts

	Risk-Ratios of Incident Brain Infarcts (RR 95% CI)			
Potential Risk-Factor	**Overall**	**Subcortical**	**Cortical**	**Cerebellar**
Age per 5 years	**1.45 (1.25–1.70)**	1.19 (0.99–1.43)	**1.59 (1.28–1.97)**	**1.45 (1.24–1.69)**
Sex (men vs. women)	**1.83 (1.49–2.25)**	**2.27 (1.54–3.33)**	**2.85 (2.05–3.95)**	**1.32 (1.03–1.70)**
Presence at Baseline (1+ vs 0)	**3.06 (2.50–3.75)**	**5.76 (3.89–8.52)**	**4.26 (3.00–6.06)**	**2.96 (2.28–3.86)**
Hypertension (yes vs no)	**1.93 (1.21–3.07)**	1.40 (0.54–3.62)	1.29 (0.61–2.76)	**3.27 (1.59–6.74)**
Systolic Blood Pressure	1.09 (0.99–1.19)	**1.20 (1.03–1.40)**	1.02 (0.88–1.19)	1.10 (0.99–1.23)
Diastolic Blood pressure	1.02 (0.90–1.16)	**1.29 (1.02–1.64)**	0.89 (0.72–1.10)	1.04 (0.91–1.20)
Diabetes Mellitus (yes vs no)	1.21 (0.86–1.71)	1.54 (0.92–2.60)	1.03 (0.61–1.73)	1.25 (0.85–1.82)
Smoking (current vs never)	1.00 (0.71–1.42)	1.00 (0.53–1.88)	0.84 (0.51–1.39)	1.11 (0.70–1.75)
Smoking (quit vs never)	0.96 (0.76–1.21)	0.94 (0.61–1.45)	0.90 (0.62–1.29)	1.01 (0.76–1.34)
Atrial Fibrillation	1.09 (0.73–1.64)	0.64 (0.27–1.51)	1.31 (0.68–2.52)	1.07 (0.68–1.69)
Carotid Plaque (≥mod plaque)	**1.27 (1.01–1.59)**	1.03 (0.68–1.57)	**1.93 (1.29–2.89)**	1.07 (0.81–1.40)
Migraine (yes vs no)	1.24 (0.94–1.63)	0.79 (0.40–1.58)	1.16 (0.72–1.88)	**1.40 (1.00–1.96)**
Migraine with aura (yes vs no)	1.44 (0.96–2.16)	1.19 (0.51–2.82)	1.78 (0.98–3.24)	1.33 (0.79–2.24)
Use of lipid lowering medication (yes vs no)	1.03 (0.81–1.31)	0.92 (0.61–1.40)	1.28 (0.89–1.84)	0.92 (0.69–1.22)
Total Cholesterol[†]	0.95 (0.80–1.12)	0.89 (0.69–1.16)	1.09 (0.85–1.40)	0.89 (0.75–1.06)
High-Density Lipoprotein[†]	0.94 (0.82–1.08)	0.99 (0.79–1.23)	0.93 (0.75–1.14)	0.93 (0.80–1.09)
Agatston Coronary Calcium	**1.19 (1.06–1.33)**	1.05 (0.83–1.32)	**1.29 (1.05–1.59)**	**1.18 (1.03–1.35)**

For continuous risk-factors, the unit of difference was 1SD, except for age where it was 5 years. All Risk-Ratios are adjusted for age, sex and time interval between MR scans.

[†]Additionally adjusted for use of lipid lowering medication